Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tezepelumab

- PMLiVE

Synairgen sinks as AZ halts trial of asthma drug

Results from a phase II trial of inhaled antiviral therapy set to be inconclusive

- PMLiVE

Novartis says migraine prevention drug clears phase III trial

Monthly injection co-developed with Amgen could be launched in 2018

- PMLiVE

Amgen takes aim at cardio diseases with Arrowhead RNAi deal

Licenses two gene silencing programmes with up to $670m in the offing for the specialist

- PMLiVE

Boehringer buys into oncolytic viruses via €210m ViraTherapeutics deal

Option to acquire the Austrian biotech after phase I trials remains open to Boehringer 

Shire Basingstoke

Shire gives up on Momenta-partnered Humira biosimilar

Will fund programme for another 12 months while divesting ongoing activities to Momenta

- PMLiVE

Amgen’s Kyprolis scarred by head-to-head duel with Velcade

Failed to show superior progression-free survival in first-line treatment trials

Sanofi reception

Sanofi eyes March approval for dupilumab in atopic dermatitis

Analysts suggest sales could reach $2.8bn annually if licensed in eczema and asthma

- PMLiVE

Amgen claims first US go-ahead for Humira biosimilar

Amjevita receives FDA approval but faces patent infringement lawsuit from AbbVie

AstraZeneca AZ

AstraZeneca to explore link between epigenetics and respiratory diseases

Joins forces with Asthma UK, the British Lung Foundation and MRC Technology

AstraZeneca AZ

AZ hopes dosing will differentiate its severe asthma therapy

Plans to file benralizumab in EU and US by the end of the year spurred by phase III data

- PMLiVE

Merck decision to drop odanacatib lifts UCB/Amgen

Pulls plug on osteoporosis candidate after studies show high risk of stroke

- PMLiVE

Amgen agrees to take Cytokinetics’ heart failure drug into phase III

Phase II results showed significant cardiac function benefit and no adverse safety signals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links